UK markets close in 7 hours 3 minutes

Compugroup Medical SE & Co. KGaA (0MSD.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
66.20+2.20 (+3.44%)
As of 5:50PM BST. Market open.
Full screen
Loading interactive chart…
  • EQS Group

    CompuGroup Medical strengthens US business with one of the largest acquisitions in company history

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Acquisition23.11.2020 / 08:10 The issuer is solely responsible for the content of this announcement. CompuGroup Medical (CGM) is growing its US business by acquiring eMDs, Inc. (eMDs), a leading provider of healthcare IT with a focus on doctors' practices in the US, reaching an attractive size in the biggest healthcare market worldwide CGM is building an attractive platform for future growth through complementary product portfolios and the ability to provide comprehensive solutions for doctors' practices Both CGM and eMDs customers will benefit from the transaction CGM has planned additional significant investments to strengthen synergetic growthKoblenz. CompuGroup Holding USA, Inc., a 100 % subsidiary of CompuGroup Medical SE & Co. KGaA is acquiring 100 % of eMDs, Inc., based in Austin, TX/USA. Today, CompuGroup Holding USA and MDeverywhere Midco, Inc., USA, the sole indirect shareholder of eMDs, Inc., USA (jointly "eMDs"), have signed an agreement regarding the acquisition of 100 % of the shares in eMDs. The transaction is structured as a reverse triangular merger under U.S. law. eMDs' key products are Ambulatory Information Systems and outsourcing services for medical accounting. With this acquisition, the US subsidiary of CGM significantly broadens its position and will become the top 4 provider in the market for Ambulatory Information Systems in the US. The consideration to be paid to the current shareholders of eMDs is based on an enterprise value of USD 240 million (equal to approx. EUR 203 million), which will be adjusted inter alia for amounts of cash, financial debt and net working capital (compared to a reference amount) as of the closing date. In the fiscal year 2019/2020 year (ended 2020/03/31), eMDs had revenues of approximately EUR 81 million and an adjusted EBITDA of approximately EUR 12 million with more than 60.000 healthcare providers."The fit with our existing product portfolio is perfect. We have established a solid foundation in the United States in recent years and are already number 2 in the important field of Laboratory Information Systems for Physician Owned Labs (POLs) and Reference Labs," said Frank Gotthardt, founder and CEO of CompuGroup Medical SE & Co. KGaA. The Germany-based corporation is one of the leading providers for eHealth solutions worldwide. "We are firmly convinced that both CGM and eMDs customers will benefit from this transaction through complementary product strengths."Dr. Ralph Körfgen, Managing Director Ambulatory & Pharmacy Information Systems, added: "With one of the largest acquisitions in the history of CGM, we will remarkably increase our installed customer base in the US. At the same time, 1,400 new colleagues will bring along valuable skills and expert knowledge. By combining products and through our planned investment, we will jointly generate high and long-term added value for healthcare professionals.""With eMDs we are considerably enhancing our product portfolio in the United States," said Benedikt Brückle, Senior Vice President USA & Canada. "We are acquiring innovative and strongly growing products here, which have recently been recognized with several awards by KLAS. I am looking forward to more than 60,000 healthcare professionals in 32,000 facilities and more than 100 effective distribution partners, who will become an important building block of the CGM success story in the United States.""With CompuGroup Medical, we have found a partner that understands the US Health IT and technology-enabled services business and shares our goal of market leadership and further driving the digitization of healthcare. We are looking forward to working jointly on innovative eHealth solutions for our common customers," said Derek Pickell, CEO eMDs.eMDs' customer base today consists of more than 60,000 providers in more than 70 disciplines. eMDs is operating in the highly attractive US healthcare IT market that shows a high equipment rate with IT solutions for healthcare professionals. eMDs has more than 1,400 employees at locations in the United States and India.Closing of the transaction is expected by the end of 2020 and is in particular subject to approvals by the U.S. merger control and investment control authorities. About CompuGroup Medical SE & Co. KGaACompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.5 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 6,300 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system. Contact for media representatives:Michael FranzHead of Brand CommunicationP +49 (0) 261 8000-6100F +49 (0) 261 8000-3100E-mail: press@cgm.com Contact for analysts and investors:Claudia ThoméHead of Investor RelationsP +49 (0) 261 8000-7030F +49 (0) 261 8000-3200E-mail: claudia.thome@cgm.com23.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1149811   End of News DGAP News Service

  • EQS Group

    CompuGroup Medical SE & Co. KGaA acquires eMDs

    CompuGroup Medical SE & Co. KGaA / Key word(s): Mergers & AcquisitionsCompuGroup Medical SE & Co. KGaA acquires eMDs23-Nov-2020 / 08:08 CET/CESTDisclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.Today, CompuGroup Holding USA, Inc., a 100 % subsidiary of CompuGroup Medical SE & Co. KGaA ("Company"), and MDeverywhere Midco, Inc., USA, the sole indirect shareholder of eMDs, Inc., USA (jointly "eMDs"), have entered into an agreement regarding acquisition of 100 % issued and outstanding capital stock of eMDs. The competent corporate bodies of the Company have already approved the transaction.eMDs' key products are Ambulatory Information Systems and outsourcing services for the accounting of medical services. CGM is thus strengthening its position in the USA significantly and, after the acquisition, will be the top 4 in the market for Ambulatory Information Systems in the USA based on the number of independent doctors' practices which are not part of a hospital.The transaction is structured as a reverse triangular merger under U.S. law. The consideration to be paid to the current shareholders of eMDs is based on an enterprise value of approx. USD 240 million (approx. EUR 203 million), which will be adjusted inter alia for amounts of cash, financial debt and net working capital (compared to a reference amount) as of the closing date. In the fiscal year 2019/2020 (ended 2020/03/31), eMDs generated revenues of approx. EUR 81 million and an EBITDA of approx. EUR 12 million with more than 60.000 healthcare providers.Closing of the transaction is expected by the end of 2020 and is in particular subject to approvals by the U.S. merger control and investment control authorities.23-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1149807   End of Announcement DGAP News Service

  • EQS Group

    CompuGroup Medical with a record quarter

    DGAP-News: CompuGroup Medical SE & Co. KGaA / Key word(s): Quarterly / Interim Statement05.11.2020 / 07:48 The issuer is solely responsible for the content of this announcement. Company successfully continues growth and investment course Significant increase in revenues and profits compared to the same quarter of the previous year, boosted by completion and rollout of new functions for the Telematics Infrastructure and by HIS acquisition Strong revenue growth across all segments Hospital segment is growing significantly, also boosted by the acquisition of parts of the Cerner portfolio After an excellent third quarter, free cash flow is now also cumulatively above previous year Groundbreaking resolutions such as the Hospital Future Act open up additional potential Koblenz. With the financial report published today, CompuGroup Medical (CGM) looks back on the strongest quarter in the company's history. The Koblenz-based company, one of the leading providers of eHealth solutions worldwide, is also entirely on schedule for the first nine months of the year, whereby the prolonged coronavirus pandemic and the corresponding measures restrict visibility with regard to future economic development. At the same time, the company is benefiting from the ongoing digitization of the healthcare system, which has seen a significant boost in the wake of the pandemic. For example, trend-setting decisions such as the Hospital Future Act (Krankenhauszukunftsgesetz, KHZG), through which several billion euros are to be made available to hospitals, should further accelerate digitization. With the acquisition of parts of the Cerner product portfolio in the field of Hospital Information Systems in Germany and Spain, which was completed on July 1, 2020, CompuGroup Medical is excellently positioned to make these opportunities available to customers."The months that lie behind us have impressively demonstrated that our decades of global efforts to digitize the healthcare system pay off," emphasizes Frank Gotthardt, founder and CEO of CompuGroup Medical. "With the next important steps in the Telematics Infrastructure and the Hospital Future Act - to name just two important measures from Germany - many millions of people will benefit from a modern, efficient and safe healthcare system. We will rigorously carry on our consistent growth course, continue to invest consistently in software and product development and thus play a leading and decisive role in shaping future developments."Michael Rauch, Chief Financial Officer (CFO), adds: "In addition to a very strong free cash flow, we are particularly pleased in this record quarter about the very positive development of our hospital segment, which has shown an impressive increase both organically and as a result of acquisitions, and about the positive revenue and profit effects from the Telematics Infrastructure rollout in the medical and pharmacy business. In the short term, we are currently living in a time characterized by uncertainty, but the business development of the last few months and the global, unprecedented acceleration in the digitization of health systems encourage us to further increase innovation investments for future growth."Group: Strong revenue growth and improved marginIn the third quarter, revenues rose by 30 % (organic: 17 %) to the record value of EUR 231.3 million (previous year: EUR 177.9 million). The adjusted Group EBITDA sits at EUR 67.1 million compared to EUR 47.3 million in the previous year's quarter. The adjusted margin, at 29 % (previous year: 27 %), is somewhat higher than in the same quarter of the previous year. In the third quarter, CGM generated a consolidated profit of EUR 34.9 million, which is clearly above the previous year's quarter (EUR 18.1 million). The adjusted profit per share (diluted) was EUR 0.71, which is also significantly above the previous year's value (EUR 0.51). For the first nine months of 2020, this means growth in consolidated revenues of 10 % to EUR 594.3 million (previous year: EUR 539.7 million) with an adjusted Group EBITDA of EUR 155.2 million (previous year: EUR 141.5 million).The free cash flow was EUR 31.8 million and thus significantly above the value from the same quarter of the previous year (EUR 2.8 million). The investments (CAPEX), at EUR 10.2 million, were below the previous year's value (EUR 14.7 million). The net debt as of the reporting date on September 30, 2020 sank when compared with December 31, 2019 by EUR 172.9 million to EUR 294.0 million. As of September 30, 2020, CompuGroup Medical employed around 6,300 employees and thus approx. 700 more than at the end of 2019, of which approx. 400 were as a result of acquisitions.CompuGroup Medical confirms the already raised guidance for revenues and adjusted EBITDA from August 6, 2020. For the year 2020, revenues in the range of EUR 820 million to EUR 860 million are still expected. The adjusted EBITDA is forecast to be within the region of EUR 205 million to EUR 220 million. However, the guidance for the 2020 fiscal year is still subject to greater uncertainty than usual due to the ongoing coronavirus pandemic.Segments: Clearly positive business development across all segmentsIn the Ambulatory Information Systems (AIS) segment, the approval of KoCoBox MED+ as the first e-health connector in Germany and the associated software upgrade for around 56,000 medical and dental practices have led to a significant growth in revenues of 19 % to EUR 128.7 million (previous year: EUR 108.0 million), whereby organic revenues have increased from EUR 106.8 million to EUR 124.9 million by 17 %. In addition, CGM KIM was the first specialist service to be approved for the important application of KIM (Kommunikation im Medizinwesen - communication in medicine). The adjusted EBITDA increased to EUR 60.2 million (previous year: EUR 39.5 million).Business in the Pharmacy Information Systems (PCS) segment was significantly shaped by the rollout of the Telematics Infrastructure in pharmacies in Germany in the third quarter, in addition to good operational business development. Revenues increased by 26 % to EUR 34.9 million (previous year: EUR 27.7 million), organic revenues rose equally to EUR 34.7 million (previous year: EUR 27.5 million). EBITDA increased by 30 % to EUR 8.6 million (previous year: EUR 6.6 million).The Hospital Information Systems (HIS) segment developed particularly strong in the past quarter. In addition to the newly acquired parts of Cerner's IT healthcare portfolio, the other business areas of the segment also showed strong overall development. Services in connection with the introduction of the Telematics Infrastructure and the "Nökis" rollout in Lower Austria also contributed to the positive development of segment revenues. Overall, revenues in this segment improved by 80 % to EUR 56.1 million (previous year: EUR 31.2 million). The organic revenue growth of 10 % is based on particularly good development in the hospital business in the DACH region and Poland. The adjusted EBITDA amounted to EUR 7.7 million (previous year: EUR 3.1 million) with an operating margin of 14 % (previous year: 10 %).The Consumer & Health Management Information Systems (CHS) segment increased revenues by 5 % to EUR 11.6 million (previous year: EUR 11.0 million), whereby the organic revenues could be increased by 10 % to EUR 12.1 million (previous year: EUR 11.0 million). The positive revenue development is mainly due to the German Intermedix division. The CGM LIFE division was able to add upon its previous positive development in the third quarter of 2020. The adjusted EBITDA amounted to EUR 1.9 million and was EUR 2.0 million below previous year's figure mainly due to increased development expenses.The complete half year report is available on the company's website at www.cgm.com under Investor Relations.About CompuGroup Medical SE & Co. KGaACompuGroup Medical is one of the leading eHealth companies in the world. With a revenue base of EUR 746 million in 2019, its software products are designed to support all medical and organizational activities in doctors' offices, pharmacies, laboratories and hospitals. Its information services for all parties involved in the healthcare system and its web-based personal health records contribute towards safer and more efficient healthcare. CompuGroup Medical's services are based on a unique customer base of more than 1.5 million users, including doctors, dentists, pharmacists and other health professionals in inpatient and outpatient facilities. With locations in 18 countries and products in 56 countries worldwide, CompuGroup Medical is the eHealth company with one of the highest coverages among eHealth service providers. Approximately 6,300 highly qualified employees support customers with innovative solutions for the steadily growing demands of the healthcare system.Contact for media representatives:Michael FranzHead of Brand CommunicationP +49 (0) 261 8000-6100F +49 (0) 261 8000-3100E-mail: press@cgm.comContact for analysts and investors:Claudia ThoméHead of Investor RelationsP +49 (0) 261 8000-7030F +49 (0) 261 8000-3200E-mail: claudia.thome@cgm.com05.11.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de Language: English Company: CompuGroup Medical SE & Co. KGaA Maria Trost 21 56070 Koblenz Germany Phone: +49 (0)261 8000 7030 Fax: +49 (0)261 8000 3200 E-mail: investor@cgm.com Internet: www.cgm.com ISIN: DE000A288904 WKN: A28890 Indices: MDAX, TecDAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange EQS News ID: 1145660   End of News DGAP News Service